Welcome to our dedicated page for CURANEX PHARMACEUTICALS news (Ticker: CURX), a resource for investors and traders seeking the latest updates and insights on CURANEX PHARMACEUTICALS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CURANEX PHARMACEUTICALS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CURANEX PHARMACEUTICALS's position in the market.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company, announced the full exercise of the over-allotment option by lead underwriter Dominari Securities LLC following its IPO. The underwriters purchased an additional 562,500 shares at $4.00 per share, raising an extra $2.25 million.
The total gross proceeds from the IPO now amount to $17.25 million through the issuance of 4,312,500 total shares. The offering was led by Dominari Securities LLC, with Pacific Century Securities and Revere Securities as co-underwriters. The registration statement became effective on August 12, 2025.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has successfully completed its Initial Public Offering (IPO). The company raised $15 million in gross proceeds through the offering of 3,750,000 shares at $4.00 per share.
Trading of CURX shares commenced on the Nasdaq Capital Market on August 26, 2025. The underwriters, led by Dominari Securities LLC, have a 45-day option to purchase up to 562,500 additional shares at the public offering price, less underwriting discounts and expenses.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has announced the pricing of its initial public offering of 3,750,000 shares at $4.00 per share.
The IPO is expected to raise $15 million in gross proceeds before deducting underwriting costs. Trading will commence on August 26, 2025 on the Nasdaq Capital Market. Underwriters have a 45-day option to purchase up to 562,500 additional shares.
Proceeds will fund the development of their lead product Phyto-N for ulcerative colitis, conduct FDA-required toxicology studies, prepare an IND application, and provide working capital. Dominari Securities leads the underwriting, with Pacific Century Securities and Revere Securities as co-underwriters.
FAQ
What is the current stock price of CURANEX PHARMACEUTICALS (CURX)?
What is the market cap of CURANEX PHARMACEUTICALS (CURX)?
